|
WO2021026124A1
|
|
Ganaxolone for use in treatment of status epilepticus
|
|
WO2020118142A1
|
|
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|
|
US2019160078A1
|
|
Ganaxolone for use in treating genetic epileptic disorders
|
|
US2019111059A1
|
|
Compositions and methods for treating autism spectrum disorder
|
|
US2018296487A1
|
|
Sustained release injectable neurosteroid formulations
|
|
US2019321375A1
|
|
Method of administering a neurosteroid to effect electroencephalographic (eeg) burst suppression
|
|
US2018071315A1
|
|
Methods of treating certain depressive disorders and delirium tremens
|
|
EP3362042A1
|
|
Injectable neurosteroid formulations containing nanoparticles
|
|
CN107427458A
|
|
Intravenous ganaxolone preparation and its purposes in treatment status epilepticus and other seizure disorders
|
|
CA2769820A1
|
|
Method for making 3.alpha.-hydroxy, 3.beta.- methyl-5.alpha.-pregnan-20-one (ganaxolone)
|
|
WO2005098428A2
|
|
Method and system for screening compounds for muscular and/or neurological activity in animals
|
